Association of circulating galectin‐3 with gestational diabetes mellitus, progesterone, and insulin resistance. Issue 1 (2nd September 2020)

• Record Type: Journal Article
• Authors: Zhang, Zeqing; Kang, Xuehui; Guo, Yaming; Zhang, Jianhua; Xie, Junhui; Shao, Shiying; Xiang, Ying; Chen, Gang; Yu, Xuefeng
• Is Part Of: Journal of diabetes. Volume 13:Issue 1(2021)
• Page Start: 54
• Page End: 62
• Publication Date: 2020-09-02
• Subjects: galectin‐3 -- gestational diabetes mellitus -- insulin resistance -- progesterone; galectin‐3 -- 妊娠期糖尿病 -- 胰岛素抵抗 -- 孕酮; Diabetes -- Periodicals; 618.3646005
• DOI: 10.1111/1753-0407.13088
• Languages: English
• ISSNs: 1753-0393

Abstract

Abstract: Background/Objective: Because galectin‐3 has been proposed to regulate obesity and insulin resistance in mice, we hypothesized that circulating galectin‐3 levels are associated with presence of gestational diabetes mellitus (GDM), progesterone, and insulin resistance. Methods: Circulating galectin‐3 levels were measured using an enzyme‐linked immunosorbent assay (ELISA) in women with GDM (n = 137) and their controls (n = 81). Associations of galectin‐3 and progesterone with GDM and insulin resistance were evaluated using regression models. Results: Circulating galectin‐3 levels were increased in the individuals with GDM ( P < .001) and associated significantly with progesterone (r = 0.42, P < .001), gestational age at sampling (r = 0.23, P < .001), current body mass index (BMI; r = 0.17, P = .02), estrogen (r = 0.15, P < .03), fasting glucose (r = 0.41, P < .001), fasting insulin (r = 0.39, P < .001), and homeostasis model assessment of insulin resistance (HOMA‐IR; r = 0.44, P < .001). After adjustment for potential confounders, including current BMI, subjects in the highest tertile of galectin‐3 levels were more likely to have GDM (odds ratio 4.71, 95% confidence interval 2.01‐11.06) as compared with the lowest tertile. The association between circulating galectin‐3 levels and GDM remained significant after adjusting for progesterone, but significantly attenuated after adjustment with HOMA‐IR. Furthermore, the multiple linear regression analyses after adjustment for confounders showed an independent association between galectin‐3 levels and HOMA‐IR (β = .41, P < .001), suggesting that association of circulating gelactin‐3 levels with GDM might be mediated via insulin resistance. Progesterone demonstrated the expected associations with galectin‐3, GDM, and HOMA‐IR. Conclusions: Circulating galectin‐3 levels are associated with GDM possibly through increased insulin resistance. The association of galectin‐3 with progesterone highlights a potential role of progesterone in its interaction with galectin‐3. Abstract : Highlights Circulating galectin‐3 levels are elevated in women with gestational diabetes mellitus. Galectin‐3 is associated with higher level of progesterone, insulin resistance, and the presence of gestational diabetes mellitus. Association of elevated levels of galectin‐3 with increased risk for gestational diabetes mellitus are mainly involved in insulin resistance. 摘要: 背景: 由于半乳糖凝集素‐3(galectin‐3)被认为可以调节小鼠的肥胖和胰岛素抵抗, 我们假设循环galectin‐3水平与妊娠期糖尿病(GDM)、孕酮和胰岛素抵抗有相关性。 方法: 采用酶联免疫吸附法(ELISA)测定GDM患者( n =137)和对照组( n =81)血清中循环galectin‐3的水平。用回归模型评估galectin‐3和孕酮、GDM以及胰岛素抵抗的关系。 结果: GDM患者血清galectin‐3水平相比对照组显著升高( P <0.001)。血清galectin‐3水平还与孕酮(r=0.42, P <0.001)、孕妇孕周(r=0.23, P <0.001)、采样时的体重指数(BMI; r=0.17, P =0.02)、雌激素水平(r=0.15, P <0.03)、空腹血糖水平(r=0.41, P <0.001)、空腹胰岛素水平(r=0. 0.39, P <0.001)以及胰岛素抵抗(HOMA‐IR; r=0.44, P <0.001)都存在显著的相关性。校正潜在的混杂因素(包括采样时的BMI)后, galectin‐3水平在最高三分位的受试者相比最低三分位者更可能患有GDM(比值比 OR =4.71, 95%置信区间 2.01~11.06)。 Logistic 回归分析校正孕酮后, 循环galectin‐3水平与GDM仍显著相关, 但在调整HOMA‐IR后, 这种相关性却明显减弱。此外, 校正混杂因素后的多元线性回归分析显示galectin‐3水平与HOMA‐IR之间存在独立的相关性(β=.41, P <0.001), 提示循环gelactin‐3水平与GDM的关联可能是通过胰岛素抵抗介导的。与预期一致, 孕酮与galectin‐3、GDM和HOMA‐IR也具有相关性。 结论: 循环galectin‐3水平可能通过增加胰岛素抵抗与GDM相关联。galectin‐3与孕酮的密切联系提示两者之间存在潜在的相互作用。